The published record on Dihexa is small, almost entirely preclinical, and considerably narrower than the claims that circulate about it. Dihexa, also written N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide and appearing in some development documents as PNB-0408, is a synthetic angiotensin IV analog whose primary evidence consists of cultured hippocampal neuron experiments and rat behavioral work. The distance between a rodent water maze result and a clinically meaningful cognitive effect in a person is large, and for this molecule it has not been bridged.
The entire published Dihexa evidence base is preclinical, consisting of cultured neuron experiments and rat behavioral studies, with no published randomized controlled trial, human pharmacokinetic data, or formal long-term toxicology package.
Counted honestly, the primary literature runs to roughly a dozen original research papers plus a handful of reviews, patent filings, and conference abstracts. A mature pharmacological candidate can carry hundreds of publications, so the volume itself is a finding. Most of the work traces back to one academic program, the angiotensin IV analog research associated with Washington State University, which leaves the record without the independent, geographically separate replication that gives a result durability.
The Dihexa literature comprises roughly a dozen primary research papers, overwhelmingly in vitro neuron cultures and rodent behavioral studies from a single research lineage, with no randomized controlled human trial in the indexed clinical record.
Almost all of the widely cited behavioral evidence rests on a single paradigm: the Morris water maze, where a rat learns the location of a hidden platform in opaque water using room cues, and learning is scored as the shrinking time and distance needed to reach it. Restoring maze performance in an animal whose cholinergic signalling was pharmacologically blocked is a rescue result under an artificial deficit, not a demonstration of improved memory in an unimpaired subject.
The rodent cognition evidence rests on Morris water maze performance recovered under scopolamine-induced or age-related impairment, an animal rescue result in spatial navigation rather than a measure of the episodic, verbal, and executive functions people mean by human cognition.
The design started from angiotensin IV, a renin-angiotensin fragment already observed to improve learning in animals, with the goal of a small, metabolically stable analog that kept the activity. The published hypothesis is that Dihexa binds hepatocyte growth factor and potentiates its signalling through the receptor tyrosine kinase c-Met, a coherent candidate pathway rather than a confirmed mechanism. The same axis is a documented driver of proliferation, invasion, and metastasis in several human cancers, so the mechanism carries a safety question and not only an explanation.
The proposed mechanism, potentiation of hepatocyte growth factor signalling at c-Met, remains a working hypothesis weakened by the April 2025 retraction of the 2014 paper reporting that the spine-forming effect disappears when c-Met signalling is blocked.
The figure repeated as roughly seven orders of magnitude, or about ten million times more potent than brain-derived neurotrophic factor, comes from one in vitro comparison of the concentration needed to increase dendritic spine formation in cultured hippocampal neurons. Potency describes how little of a substance moves a specific endpoint; it says nothing about how large or how useful the resulting effect is in an intact brain where absorption, distribution, metabolism, and feedback regulation all intervene.
| Criterion | Dihexa | Brain-derived neurotrophic factor |
|---|---|---|
| Assay measured | Dendritic spine formation in cultured hippocampal neurons | The same cell-culture assay |
| Active concentration | Picomolar range | Substantially higher concentrations |
| What the number describes | Amount needed to move one endpoint | Amount needed to move one endpoint |
| Human evidence for the comparison | None published | No head to head human study exists |
The claim that Dihexa is roughly ten million times more potent than brain-derived neurotrophic factor describes picomolar activity in a single cultured-neuron spine assay, not a measured advantage in human memory, and no head to head human study of the two exists.
No. There is no completed or reported randomized controlled trial of Dihexa in people, and no peer-reviewed human pharmacokinetic, safety, or dosing study establishing what the compound does in a human body, how much reaches the brain, or how it is cleared. One commercial thread is often mangled in retellings: the academic angiotensin IV analog program was licensed to a small biotechnology company, and a clinical-stage candidate from that broader hepatocyte growth factor and c-Met line did enter human trials for neurodegenerative disease, but that candidate is a distinct molecule.
Dihexa has never been tested in a published randomized controlled human trial, and no peer-reviewed human pharmacokinetic, safety, or dosing study exists, so every animal finding stands as a hypothesis about people rather than a finding about them.
Safety is where the evidence gap is widest and where the consequences of that gap are most serious. No published regulatory-grade toxicology package covers what a medicines regulator would require before human exposure: repeat-dose toxicity across two species, genotoxicity, carcinogenicity, reproductive and developmental toxicity, and safety pharmacology. The rodent work that was run tested efficacy over short treatment windows, and an efficacy study in a small group of rats cannot detect delayed, cumulative, or low-frequency harm.
No published regulatory-grade toxicology package exists for Dihexa covering repeat-dose toxicity, genotoxicity, carcinogenicity, or reproductive and developmental toxicity, and the proposed c-Met potentiation mechanism amplifies a pathway that oncology drug development has mostly targeted for inhibition.
Several limitations compound one another here, and none of them is unusual for early preclinical work, which is exactly the point. Whole categories of outcome were never studied at all, including chronic dosing effects, dependence, withdrawal, effects in healthy young subjects, and long-term structural imaging. Add the ordinary asymmetry of scientific publishing, where positive results reach print and null replications often do not, and the published picture is probably the most favorable version of the evidence rather than a balanced one.
The rodent behavioral experiments ran roughly eight to twelve animals per condition inside a single research lineage, and that lineage now carries a 2021 notice of concern on the 2013 characterization paper and an April 2025 retraction of the 2014 mechanism paper.
Placing the compound on the evidence ladder settles the comparison without any rhetoric. The rungs run from biochemical and cell-culture work, up through animal models, human safety and pharmacokinetic studies, small controlled trials of effect, large randomized trials with clinical endpoints, and finally post-marketing experience across large populations. Dihexa sits on the second rung, and frequent discussion in enthusiast communities is not a tier of evidence.
| Evidence rung | Dihexa | Approved Alzheimer type medication |
|---|---|---|
| Cell-culture pharmacology | Reached | Reached |
| Animal efficacy models | Reached | Reached |
| Human safety and pharmacokinetics | None published | Characterized |
| Randomized clinical endpoint trials | None | Thousands of participants |
| Post-marketing safety record | None | Published adverse event tables |
Dihexa has reached only the second rung of the evidence ladder, cell-culture pharmacology plus a rodent efficacy signal, while an approved dementia medication carries human pharmacokinetics, thousands of trial participants, published adverse event tables, and defined dosing and interactions.
Regulatory status here is not a bureaucratic footnote, it is a direct statement about how much is known. No major regulator has approved Dihexa, which means no authority has ever reviewed a dossier of manufacturing, toxicology, pharmacokinetic, and efficacy data and concluded that benefits outweigh risks for any indication or dose.
Dihexa is not approved as a medicine by any major regulator and does not qualify as a dietary supplement ingredient, which is why it carries research-use-only or not-for-human-consumption labeling, and its growth factor activity places it under the catch-all prohibited categories in sport.
Educational use only. This article describes what the published scientific and clinical literature reports about Dihexa. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
